FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2339158755> ?p ?o ?g. }

• W2339158755 endingPage "7" @default.
• W2339158755 startingPage "4320" @default.
• W2339158755 abstract "To assess the clinical efficacy and safety of Silibinin in preventing drug-induced liver injury (DILI) in the general population (high-risk patients with non-drug induced liver injury).A prospective, multi-center, randomized, open-label and controlled trial was conducted with 568 patients undergoing primary treatment of pulmonary tuberculosis. The study included 277 patients in experimental group and 291 patients in control group. The patients in the two group were treated with conventional 2HREZ (S)/4HR for tuberculosis (TB), and additional Silibinin capsules (oral administration of 70 mg/time, 3 times/day for 8 weeks in experimental group. Outcomes of liver function, interruption of anti-TB treatment and therapeutic results, as well as adverse reactions were observed and analyzed.At 2, 4 and 8 weeks of treatment, the incidences of liver injury in experimental group were 3.97%, 1.44% and 2.17%, respectively; the incidences in control group were 4.12%, 4.12% and 2.41%, respectively. Statistical analysis showed that there was no difference in the incidence between the two groups at each treatment period (P>0.05). At 8 weeks, the numbers of patients diagnosed of DILI were 18 (7.22%) and 27 (9.28%) in experimental and control groups, respectively (P>0.05). 34.30% and 27.49% of the patients in experimental and control groups had transient abnormal liver function or symptoms, respectively; similar percentages (3.25% and 6.19%) of the patients in two groups have liver function injury and symptoms, and were suspended for anti-TB treatment (P>0.05). The incidence of anorexia and nausea symptoms was lower in experimental group than in control group, and the differences were significant at 4 and 8 weeks (P<0.05). 8 weeks after the treatment, 98.30% of the sputum smear culture were negative in experimental group, which was significantly higher (P<0.01) than that in control group (92.98%).Preventive hepatoprotective therapy in the general population may reduce drug discontinuation rate, improve patient's compliance and outcomes of anti-TB treatment." @default.
• W2339158755 created "2016-06-24" @default.
• W2339158755 creator A5004282357 @default.
• W2339158755 creator A5009366691 @default.
• W2339158755 creator A5010494056 @default.
• W2339158755 creator A5033516594 @default.
• W2339158755 creator A5037747000 @default.
• W2339158755 creator A5038819595 @default.
• W2339158755 creator A5039229598 @default.
• W2339158755 creator A5043942510 @default.
• W2339158755 creator A5050213145 @default.
• W2339158755 creator A5054763642 @default.
• W2339158755 creator A5062952756 @default.
• W2339158755 creator A5068183779 @default.
• W2339158755 creator A5075381572 @default.
• W2339158755 creator A5077857097 @default.
• W2339158755 date "2015-01-01" @default.
• W2339158755 modified "2023-10-18" @default.
• W2339158755 title "An open-label, randomized and multi-center clinical trial to evaluate the efficacy of Silibinin in preventing drug-induced liver injury." @default.
• W2339158755 cites W2002955711 @default.
• W2339158755 cites W2016409720 @default.
• W2339158755 cites W2021767023 @default.
• W2339158755 cites W2028434983 @default.
• W2339158755 cites W2044422047 @default.
• W2339158755 cites W2049957653 @default.
• W2339158755 cites W2067258538 @default.
• W2339158755 cites W2067560218 @default.
• W2339158755 cites W2089145440 @default.
• W2339158755 cites W2104945935 @default.
• W2339158755 cites W2119751640 @default.
• W2339158755 cites W2411022095 @default.
• W2339158755 cites W4253457069 @default.
• W2339158755 cites W66300265 @default.
• W2339158755 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4443182" @default.
• W2339158755 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26064348" @default.
• W2339158755 hasPublicationYear "2015" @default.
• W2339158755 type Work @default.
• W2339158755 sameAs 2339158755 @default.
• W2339158755 citedByCount "12" @default.
• W2339158755 countsByYear W23391587552015 @default.
• W2339158755 countsByYear W23391587552016 @default.
• W2339158755 countsByYear W23391587552019 @default.
• W2339158755 countsByYear W23391587552020 @default.
• W2339158755 countsByYear W23391587552021 @default.
• W2339158755 countsByYear W23391587552022 @default.
• W2339158755 countsByYear W23391587552023 @default.
• W2339158755 crossrefType "journal-article" @default.
• W2339158755 hasAuthorship W2339158755A5004282357 @default.
• W2339158755 hasAuthorship W2339158755A5009366691 @default.
• W2339158755 hasAuthorship W2339158755A5010494056 @default.
• W2339158755 hasAuthorship W2339158755A5033516594 @default.
• W2339158755 hasAuthorship W2339158755A5037747000 @default.
• W2339158755 hasAuthorship W2339158755A5038819595 @default.
• W2339158755 hasAuthorship W2339158755A5039229598 @default.
• W2339158755 hasAuthorship W2339158755A5043942510 @default.
• W2339158755 hasAuthorship W2339158755A5050213145 @default.
• W2339158755 hasAuthorship W2339158755A5054763642 @default.
• W2339158755 hasAuthorship W2339158755A5062952756 @default.
• W2339158755 hasAuthorship W2339158755A5068183779 @default.
• W2339158755 hasAuthorship W2339158755A5075381572 @default.
• W2339158755 hasAuthorship W2339158755A5077857097 @default.
• W2339158755 hasConcept C120665830 @default.
• W2339158755 hasConcept C121332964 @default.
• W2339158755 hasConcept C126322002 @default.
• W2339158755 hasConcept C141071460 @default.
• W2339158755 hasConcept C142724271 @default.
• W2339158755 hasConcept C168563851 @default.
• W2339158755 hasConcept C197934379 @default.
• W2339158755 hasConcept C2776637226 @default.
• W2339158755 hasConcept C2777130413 @default.
• W2339158755 hasConcept C2780035454 @default.
• W2339158755 hasConcept C2781069245 @default.
• W2339158755 hasConcept C2908647359 @default.
• W2339158755 hasConcept C2992208098 @default.
• W2339158755 hasConcept C535046627 @default.
• W2339158755 hasConcept C61511704 @default.
• W2339158755 hasConcept C71924100 @default.
• W2339158755 hasConcept C90924648 @default.
• W2339158755 hasConcept C98274493 @default.
• W2339158755 hasConcept C99454951 @default.
• W2339158755 hasConceptScore W2339158755C120665830 @default.
• W2339158755 hasConceptScore W2339158755C121332964 @default.
• W2339158755 hasConceptScore W2339158755C126322002 @default.
• W2339158755 hasConceptScore W2339158755C141071460 @default.
• W2339158755 hasConceptScore W2339158755C142724271 @default.
• W2339158755 hasConceptScore W2339158755C168563851 @default.
• W2339158755 hasConceptScore W2339158755C197934379 @default.
• W2339158755 hasConceptScore W2339158755C2776637226 @default.
• W2339158755 hasConceptScore W2339158755C2777130413 @default.
• W2339158755 hasConceptScore W2339158755C2780035454 @default.
• W2339158755 hasConceptScore W2339158755C2781069245 @default.
• W2339158755 hasConceptScore W2339158755C2908647359 @default.
• W2339158755 hasConceptScore W2339158755C2992208098 @default.
• W2339158755 hasConceptScore W2339158755C535046627 @default.
• W2339158755 hasConceptScore W2339158755C61511704 @default.
• W2339158755 hasConceptScore W2339158755C71924100 @default.
• W2339158755 hasConceptScore W2339158755C90924648 @default.
• W2339158755 hasConceptScore W2339158755C98274493 @default.

• next